65,437 trials
Acute Otitis Media
Primary: Time to Cessation of Otorrhea — 7.69; 22; 3.75 days
Coronary Artery Disease
Primary: MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT — 4.34; 5.92 percentage of patients (KM estimate) — p=<0.001
Healthy
Primary: Serum 25-hydroxyvitamin D — 26.7; 22.4 ng/mL — p=0.003
HIV Infections · Cytomegalovirus Retinitis
Primary: Mortality — 107; 127 participants
Implantable Cardioverter-Defibrillator With Magnetic Resonance Imaging
Primary: MRI and ICD System Related Serious Adverse Device Effect (SADE) Free Rate — 100 percentage of participants
Application Site Discomfort · Medical Device Discomfort
Primary: Time in Minutes That Tq Remained Inflated — 30.5; 22.4 Minutes
Neuromuscular Blockade · Pain · Laparoscopy
Primary: Shoulder Pain — 14; 30 participants
Idiopathic Parkinson's Disease
Primary: Longitudinal Change of Brain Network Activity — 0.41; 0.61; 2.21; 3.61 Z-score in PDRP — p=0.84
Essential Hypertension
Primary: Number of Participants With Adverse Events, Serious Adverse Events, and Deaths (Analysis by Actual Treatment) — 147; 78; 53; 0 Participants
Hypogonadism
Primary: The Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of Testosterone Enanthate Formulations at 6 Weeks — 150445.2; 70955.7; 278657.9…
Non-small Cell Lung Cancer
Primary: Overall Survival (OS) Time — 32.4; 32.2 Months — p=0.828
Heart Failure · Depression
Primary: Beck Depression Inventory II — 9.3; 9.2; 9.0; 8.6 units on a scale — p=0.90
Functional Disorder of Intestine
Primary: Time to First Post-op Bowel Movement — 64; 77 hours
Diabetic Nephropathy
Primary: Percent Reduction From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 — 13.27; 5.02 percent (%)
Acute Ischemic Stroke
Primary: Incidence of Symptomatic Intracranial Hemorrhage (SICH) by Dose Cohort — 0; 0; 0 participants